Share Prices & Company Research

Stockbroking

Oncimmune Holdings

Current Price 85.00p Bid 85.00p Ask 95.00p Change 0.00%
Last Updated: 21/09/2019 21:06. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Oncimmune Holdings plc is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT tests for liver and ovarian cancer are in development.

Financial Highlights Year Ended 31/05/2018

Turnover
£0.24m
Operating Profit
£-6.37m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-7.89

Key Personnel

Dr Adam Mark Hill
Chief Executive Officer
Frank Matthew Sunderland Hall
Chief Financial Officer
Geoffrey Neil Hamilton-Fairley
Executive Vice Chairman
Meinhard Folkert Schmidt
Non-Executive Chairman
Timothy Brian Bunting
Non-Executive Dep Chairman
Andrew Vaughan Unitt
Non-Executive Director
Richard Simon Sharp
Non-Executive Director
Carsten Schroeder
Non-Executive Director
Dr Annalisa Mary Jenkins
Non-Executive Director
Julian Clement Hirst
Non-Executive Director
Dr Cheung To
Non-Executive Director

Stock Details

EPIC
ONC
ISIN
GB00BYQ94H38
Shares in Issue
63,250,217
Market cap
£56.93m
Sector

Analyst Views (0)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
90.00p
Bid Price
85.00p
Ask Price
95.00p
Volume
17133
Change Today
0.00p
% Change Today
0.00%
Open
92.50p
Previous Close
90.00p
Intraday High
92.50p
Intraday Low
85.00p
52 Week High
136.00p
52 Week Low
79.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Oncimmune Holdings Intra-day Chart

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2018
31 May 2017
Tangible Assets
0.2
0.2
Intangible Assets & Goodwill
0.7
0.5
Investments & Other Non-Current Assets
0.0
0.0
Total Non-Current Assets
0.9
0.8
Inventory
0.3
0.3
Trade & Receivables
0.3
0.3
Cash & Receivables
13.0
5.1
Other Current Assets & Assets Held for Resale
0.0
0.0
Total Assets
14.4
6.4

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2018
31 May 2017
Short Term Liabilities
0.9
1.4
Long Term Liabilities
0.0
0.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
0.9
1.4

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2018
31 May 2017
Net Assets
13.6
5.0

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2018
31 May 2017
Share Capital
0.6
0.5
Minority Interests
0.0
0.0
Retained Earnings
-49.3
-43.0
Share Premium Account
31.0
16.3
Other Equity
31.3
31.2
Total Equity
13.6
5.0

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2018
31 May 2017
Cashflow from Operating Activities
-6.1
-4.3
Cashflow Before Financing
-6.4
-4.7
Increase / Decrease in Cash
7.9
-5.1

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 May 2018
31 May 2017
Turnover
0.2
0.2
Cost of Sales
0.9
0.5
Gross Profit
-0.7
-0.3
Operating Profit
-6.4
-5.3
Pre-Tax Profit
-6.3
-5.3
Profit / Loss for the Year
-6.3
-5.0
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.